Sargramostim
- Generic Name
- Sargramostim
- Brand Names
- Leukine
- Drug Type
- Biotech
- CAS Number
- 123774-72-1
- Unique Ingredient Identifier
- 5TAA004E22
- Background
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
- Indication
For the treatment of cancer and bone marrow transplant
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Hematopoietic Subsyndrome of Acute Radiation Syndrome, Hodgkin's Lymphoma, Neutropenia, Non-Hodgkin's Lymphoma (NHL), Severe Infection
- Associated Therapies
- Allogenic bone marrow transplantation therapy, Autologous bone marrow transplantation therapy, Autologous peripheral haematopoietic stem cell transplant
Sargramostim (GM-CSF) + PD-1
- Conditions
- Unresectable MelanomaMetastatic MelanomaStage III MelanomaStage IV Melanoma
- Interventions
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT04703426
A Phase II/III Study of Sargramostim
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Nobelpharma
- Target Recruit Count
- 70
- Registration Number
- NCT04642950
- Locations
- 🇯🇵
Mishuku Hospital, Meguro-ku, Tokyo, Japan
🇯🇵Kanagawa Cardiovascular and Respiratory Center, Yokohama City, Kanagawa, Japan
🇯🇵Center Hospital of the National Center for Global Health and Medicine, Shinjuku-Ku, Tokyo, Japan
Study of Sargramostim in Patients With COVID-19
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Partner Therapeutics, Inc.
- Target Recruit Count
- 123
- Registration Number
- NCT04411680
- Locations
- 🇺🇸
Memorial Hermann Hospital Affiliated with the University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, United States
🇺🇸University of Utah Health, Salt Lake City, Utah, United States
🇺🇸St. Jude Medical Center, Fullerton, California, United States
Using GM-CSF as a Host Directed Therapeutic Against COVID-19
- Conditions
- COVIDSars-CoV2ARDS, Human
- Interventions
- Other: Normal Saline 0.9%
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Singapore General Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT04400929
- Locations
- 🇸🇬
Singapore General Hospital, Singapore, Singapore
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
- Conditions
- Ganglioneuroblastoma, NodularNeuroblastoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: FDG-Positron Emission TomographyRadiation: Iobenguane I-123Procedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition Scan
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 41
- Registration Number
- NCT04385277
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
- Conditions
- Malignant Melanoma
- Interventions
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Ultimovacs ASA
- Target Recruit Count
- 156
- Registration Number
- NCT04382664
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸California Cancer Associates for Research & Excellence (CCARE, San Marcos, California, United States
🇺🇸University of California Irvine Health, Orange, California, United States
Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- University Hospital, Ghent
- Target Recruit Count
- 87
- Registration Number
- NCT04326920
- Locations
- 🇧🇪
AZ Sint Jan Brugge, Brugge, Belgium
🇧🇪University Hospital Ghent, Gent, Belgium
🇧🇪AZ Delta Roeselare, Roeselare, Belgium
GM-CSF With Post-Transplant Cyclophosphamide
- Conditions
- Transplant-Related Hematologic Malignancy
- Interventions
- Other: Control Arm
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Northside Hospital, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT04237623
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
- Conditions
- Relapsed NeuroblastomaRefractory Neuroblastoma
- Interventions
- Biological: Natural Killer Cells
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Nationwide Children's Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT04211675
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
- Conditions
- Pleural MesotheliomaWilms TumorMesothelioma
- Interventions
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT04040231
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Commack, Commack, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.